[1] 王晨飞,胡浩霖,吕建鑫,等.乳腺癌侵袭相关分子的研究热点[J].东南大学学报(医学版),2018,37(4):734-738.
[2] ADAMCZYK A,KRUCZAK A,HARAZIN-LECHOWSKA A,et al.Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment[J].Onco Targets Ther,2018,11:4525-4535.
[3] WU Z P,XU S G,ZHOU L H,et al.Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting[J].Onco Targets Ther,2018,11:801-808.
[4] RYE I H,TRINH A,SAETERSDAL A B,et al.Intra-tumor heterogeneity defines treatment-resistant HER2+breast tumors[J/OL].Mol Oncol.https://www.biorxiv.org/content/early/2018/04/18/297549.[2018-04-18].
[5] LEE H J,SEO A N,KIM E J,et al.HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer[J].Am J Clin Pathol,2014,142(6):755-766.
[6] ELIZALDE P V,CORDO-RUSSO R I,CHERVO M F,et al.ErbB-2 nuclear function in breast cancer growth,metastasis and resistance to therapy[J].Endocr Relat Cancer,2016,23(12):243-257.
[7] VENTURUTTI L,ROMERO L V,URTREGER A J,et al.Stat3 regulates ErbB-2 expression and Co-Opts ErbB-2 nuclear function to induce MiR-21 expression,PDCD4 downregulation and breast cancer metastasis[J].Oncogene,2015,29(953):1468-1485.
[8] RUSSO R C,BÉGUELIN W,FLAQUÉ M D,et al.Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance[J].Oncogene,2015,34(26):3413-3428.
[9] MOHD-NAFI S N,GENERALI D,KRAMER-MAREK G,et al.Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer[J].Oncotarget,2014,5(15):5934-5949.
[10] NISHIMURA R,TOH U,TANAKA M,et al.Role of HER2-Related Biomarkers (HER2,p95HER2,HER3,PTEN and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab[J].Oncology,2017,93(1):51-61.
[11] DUCHNOWSKA R,SPERINDE J,CZARTORYSKA-ARŁUKOWICZ B,et al.Predictive value of quantitative HER2,HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab[J].Oncotarget,2017,8(61):104149-104159.
[12] WIMANA Z,GEBHART G,GUIOT T,et al.N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging[J].Oncotarget,2017,8(34):56185-56198.
[13] MERCOGLIANO M F,INURRIGARRO G,DE MARTINO M,et al.Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer[J].BMC Cancer,2017,17(1):895.
[14] RIMAWI M F,DE ANGELIS C,CONTRERAS A,et al.Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer[J].Breast Cancer Res Treat,2018,167(3):731-740.
[15] FAN H,LI C,XIANG Q,et al.PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer:A systematic review and meta-analysis[J].Thorac Cancer,2018,9(5):571-579.
[16] GÁMEZ-POZO A,PÉREZ CARRIÓN R M,MANSO L,et al.The Long-HER study:clinical and molecular analysis of patients with HER2+advanced breast cancer who become long-term survivors with trastuzumab-based therapy[J].PLoS One,2014,9(10):e109611.
[17] STERN H M,GARDNER H,BURZYKOWSKI T,et al.PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance[J].Clin Cancer Res,2015,21(9):2065-2074.
[18] BERNS K,SONNENBLICK A,GENNISSEN A,et al.Loss of ARID1A activates ANXA1,which serves as a predictive biomarker for trastuzumab resistance[J].Clin Cancer Res,2016,22(21):5238-5248.
[19] IKINK G J,BOER M,BAKKER E R M,et al.Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance[J].Oncogene,2018,37(12):1594-1609.
[20] KAR A,LIU B,GUTIERREZ-HARTMANN A.ESE-1 knockdown attenuates growth in trastuzumab-resistant HER2+breast cancer cells[J].Anticancer Res,2017,37(12):6583-6591.
[21] 胡雅彬,孙丽敏,陈泓宇,等.Erbin表达缺失诱导MDA-453人乳腺癌细胞对曲妥珠单抗耐药[J].军事医学,2013,37(11):831-835.
[22] SHI S J,WANG L J,YU B,et al.LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer[J].Oncotarget,2015,6(13):11652-11663.
[23] CHIHARA Y,SHIMODA M,HORI A,et al.A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells[J].Breast Cancer Res Treat,2017,166(1):55-68.
[24] CHAKRABARTY A,BHOLA N E,SUTTON C,et al.Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors[J].Cancer Res,2013,73(3):1190-1200.
[25] 王庆,彭丽萍,唐培志.STAT-3与乳腺癌关系的研究进展[J].现代医学,2015,43(12):1594-1597.
[26] AGHAZADEH S,YAZDANPARAST R.Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN[J].Biochim Biophys Acta,2017,1861(8):1970-1980.
[27] VON SCHWARZENBERG K,LAJTOS T,SIMON L,et al.V-ATPase inhibition overcomes trastuzumab resistance in breast cancer[J].Mol Oncol,2014,8(1):9-19.
[28] LIU D,YANG D,WANG T,et al.Beta2-AR signaling controls trastuzumab resistance-dependent pathway[J].Oncogene,2015,35(1):47-58.
[29] ABRAVANEL D L,BELKA G K,PAN T C,et al.Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy[J].J Clin Invest,2015,125(6):2484-2496.
[30] PANDYA K,WYATT D,GALLAGHER B,et al.PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2 Positive Breast Cancer to Reverse Trastuzumab Resistance[J].Clin Cancer Res,2016,22(1):175-186.
[31] SWAIN S M,BASELGA J,KIM S B,et al.Pertuzumab,trastuzumab,and docetaxel in HER2-positive metastatic breast cancer[J].N Engl J Med,2015,372(8):724-734.
[32] VON MINCKWITZ G,PROCTER M,de AZAMBUJA E,et al.Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer[J].N Engl J Med,2017,377(2):122-131.
[33] HURVITZ S A,MARTIN M,SYMMANS W F,et al.Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1[K])+pertuzumab (P) vs docetaxel+carboplatin+trastuzumab+P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer(EBC) (KRISTINE)[J].J Clin Oncol,2016,34(suppl):500.
[34] HARBECK N,GLUZ O,CHRISTGEN,et al.Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer:WSG-ADAPT HER2+/HR+phase Ⅱ trial[J].J Clin Oncol,2015,33(Suppl):506.
[35] VAN SWEARINGEN A E D,SIEGEL M B,DEAL A M,et al.LCCC 1025:a phase Ⅱ study of everolimus,trastuzumab,and vinorelbine to treat progressive HER2-positive breast cancer brain metastases[J].Breast Cancer Res Treat,2018,171(3):637-648.
[36] FREEDMAN R A,GELMAN R S,WEFEL J S,et al.TBCRC 022:phase Ⅱ trial of neratinib+capecitabine for patients (Pts) with human epidermal growth factor receptor 2(HER2+) breast cancer brain metastases (BCBM),in American Association of Clinical Oncology Annual Meeting[J].J Clin Oncol,2017,35(15 suppl):1005.
[37] MA F,LI Q,CHEN S,et al.Phase Ⅰ study and biomarker analysis of pyrotinib,a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor,in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J].J Clin Oncol,2017,35(27):3105-3112.
[38] WANG D S,LIU Z X,LU Y X,et al.Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer[J/OL].Gut.http://dx.doi.org/10.1136/gutjnl-2018-316522.[2018-09-29].
[39] LI H,LIU J,CHEN J,et al.A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients[J].Nat Commun,2018,9(1):1614. |
